A guide to follow-on biologics and biosimilars with a focus on insulin
R Dolinar, F Lavernia, S Edelman - Endocrine Practice, 2018 - Elsevier
Objective: Many healthcare providers in the US are not familiar with follow-on biologics and
biosimilars nor with their critical distinctions from standard generics. Our aim is to provide a …
biosimilars nor with their critical distinctions from standard generics. Our aim is to provide a …
Formulary considerations for insulins approved through the 505 (b)(2)“follow-on” pathway
JT Rasmussen, HJ Ipema - Annals of Pharmacotherapy, 2019 - journals.sagepub.com
Objective: To summarize formulary-relevant issues for follow-on insulins approved through
the Food and Drug Administration (FDA) 505 (b)(2) approval pathway (Basaglar and …
the Food and Drug Administration (FDA) 505 (b)(2) approval pathway (Basaglar and …
Quality and Efficacy Concerns with Generics in Treatment of Hepatitis C with Directly Acting Antivirals
BF Zuberi - Journal of the Dow University of Health …, 2017 - jduhs.jduhs.duhs.edu.pk
Treating hepatitis C has never been so convenient after the advent of Directly Acting
Antivirals (DAA). Convenience is at both ends; for the doctors to prescribe and for patients to …
Antivirals (DAA). Convenience is at both ends; for the doctors to prescribe and for patients to …